脂蛋白和心房动之间的关联:系统性审查和元分析
Mingyang Yang1,2, Basma Nasr3, Junzhao Liu2,4
1Department of Liver Surgery, Liver Transplantation Center, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Clinical cardiology
|July 12, 2023
概括
脂蛋白 (Lp[a]) 与新发动的心房动 (AF) 没有关联. 遗传上升的Lp[a]也没有与AF风险的联系,这表明需要对Lp[a]和AF机制进行进一步的研究.
科学领域:
- 心血管医学 心血管医学
- 遗传学 是一个遗传学.
- 流行病学 流行病学
背景情况:
- 脂蛋白 (Lp) 是已知的心血管疾病风险因素.
- 之前对Lp[a]和心房的研究已经产生了相互矛盾的结果.
- 了解Lp[a]和AF之间的关系对于评估心血管风险至关重要.
研究的目的:
- 系统地审查和分析有关Lp[a]和新发性AF之间关联的现有文献.
- 评估基因上升的Lp[a]与发展AF的风险之间的关系.
- 根据Lp[a]级分层来探索结果的潜在差异.
主要方法:
- 在2023年3月1日之前,对主要的健康科学数据库 (PubMed,Embase,Cochrane图书馆,Web of Science,MEDLINE,ScienceDirect) 进行全面的系统搜索.
- 包括通过搜索发现的九项相关研究.
- 分析以确定Lp[a]和AF之间的关联,包括基因上升的Lp[a].
主要成果:
- 在Lp[a]水平和新发性AF之间没有发现统计学意义上的关联 (HR = 1.45,95% CI: 0.57-3.67,p = 0.432).
- 遗传上升的Lp[a]与肌肉前列腺风险增加无关 (OR = 1.00,95% CI: 1.00-1.00,p = 0.461).
- 初步调查结果表明,较高的Lp[a]水平与AF风险之间可能存在反向关联,需要进一步调查.
结论:
- 目前的证据不支持Lp[a]水平与AF发病率之间的直接关联.
- 需要进一步的研究来阐明潜在的机制,并探索在较高Lp[a]度下观察到的潜在反向关系.
- 研究Lp[a]分层可能会对其在AF发展中的作用提供更细致的理解.
相关概念视频
01:30Atherosclerosis I: Introduction
11
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
11
01:30Peripheral Artery Disease I: Introduction
10
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs but also impacts other areas, such as the arms, thereby impairing overall circulation and organ function.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty deposits inside the arterial...
10
01:26Atherosclerosis III: Management
13
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
13
01:30Coronary Artery Disease I: Introduction
25
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
25
01:26Coronary Artery Disease II: Pathophysiology
13
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
13
01:38Inflammation
53.9K
Overview
53.9K